ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [4]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial's prospects, which were deemed inadequate by the FDA [5]. - The misleading statements resulted in damages to investors when the true details were revealed [5].